Anna D. Garrett, PharmD, BCPS, CPP

FOLIC ACID REDUCES RISK OF STROKE

November 1st 2007

FDA APPROVES UPDATED WARFARIN INFO

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

FONDAPARINUX MAY BE OPTION FOR HIT

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

INTERACTION REGISTRY AVAILABLE

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

META-ANALYSIS REINFORCES VALUE OF WARFARIN AND ANTIPLATELET AGENTS

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

WORLD HEALTH ORGANIZATION STUDIES TRAVEL RISKS

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

NEW ORAL ANTICOAGULANTS SHOW PROMISE IN PHASE 3 STUDIES

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

VTE RISK REDUCED WITH LONGER DURATION OF PROPHYLAXIS

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

IS NATTOKINASE A NATURAL ALTERNATIVE TO WARFARIN?

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

HIGH RATES OF WARFARIN-RELATED AEs IN NURSING HOMES

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

LONG-TERM ASPIRIN USE MAY REDUCE RISK OF SOME CANCERS

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

ACETAMINOPHEN INTERACTION MAY PUT PATIENTS AT RISK

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

FDA APPROVES FIRST BIOLOGIC TO TREAT PROTEIN C DEFICIENCY

July 1st 2007

LOW-DOSE ASPIRIN BEST FOR PREVENTING CARDIOVASCULAR DISEASE

July 1st 2007

OUT-OF-RANGE INRs COMMON AMONG WARFARIN PATIENTS IN ER

July 1st 2007

THE DEBATE CONTINUES ON LENGTH OF THERAPY

METABOLIC SYNDROME MAY CONTRIBUTE TO RISK OF VTE

WOMEN MAY NOT BENEFIT FROM ASPIRIN THERAPY

RACE MAY AFFECT FILLING OF WARFARIN PRESCRIPTIONS

ORAL CORTICOSTEROID THERAPY MAY INCREASE INR

SMOKING AFFECTS WARFARIN THERAPY

NEW ORAL ANTICOAGULANTS UNDER STUDY

ABCD SCORING VALIDATED

ANTICOAGULANT USE SUBOPTIMAL

GENETICS 101: COMMON INHERITED CLOTTING DISORDERS

BEVERAGES MAY BE SOURCE OF INR INSTABILITY

ADVISORY ISSUED REGARDING ANTIPLATELET THERAPY AFTER STENT PLACEMENT